Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1001-1011

  Li, Zhengyu ^a   Min, Wenjiao ^b   Gou, Jinhai ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Cyclophilin A; Endometrial cancer; MAPK kinase; Paclitaxel resistance; RNA interference

Indexed keywords

CYCLOPHILIN A; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; RNA; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; VINCRISTINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOPHILIN A; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84887209224     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2285-8     Document Type: Article

References (41)

1. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552-9556 (Pubitemid 23315823)
2. Hill EK, Dizon DS (2012) Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs 72(5):705-713
3. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012) Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 38(7):890-903
4. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100:1282-1293 (Pubitemid 27386315)
5. Li Z, Zhao X, Bai SN, Wang Z, Chen L, Wei Y, Huang C (2008) Proteomic identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 7:1810-1823
6. Obchoei S, Wongkhan S, Wongkham C, Li M, Yao Q, Chen C (2009) Cyclophilin A: potential functions and therapeutic target for human cancer. Med Sci Monit 15(11):RA221-32
7. Choi KJ, Piao YJ, Lim MY, Kim JH, Ha J, Choe W, Kim SS (2007) Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 67:3654-3662 (Pubitemid 46762150)
8. Chen S, Zhang M, Ma H, Saiyin H, Shen S, Xi J, Wan B, Yu L (2008) Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance. Cancer Chemother Pharmacol 61:459-469 (Pubitemid 350275981)
9. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56(5):1091-1097 (Pubitemid 26065405)
10. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-691 (Pubitemid 41114904)
11. Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS (2003) Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 51(4):297-305 (Pubitemid 36629807)
12. Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Lofvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L et al (2003) A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res 27(4):323-328
13. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86(3):302-310 (Pubitemid 35425526)
14. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein MN, Arceci RJ, Sikic BI, Dahl GV (2010) Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the children's oncology group. Pediatr Blood Cancer 54(5):694-702
15. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL (2008) The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 68(21):8881-8888
16. Bhattacharya R, Cabral F (2009) Molecular basis for class V β-tubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem 284(19):13023-13032
17. Yin S, Bhattacharya R, Cabral F (2010) Human mutations that confer paclitaxel resistance. Mol Cancer Ther 9(2):327-335
18. Natarajan K, Senapati S (2012) Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations. PLoS ONE 7(8):e42351
19. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100(5):1282-1293 (Pubitemid 27386315)
20. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, Monden M, Noguchi S (2003) Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9(8):2992-2997 (Pubitemid 36993258)
21. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G (2005) The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 65(6):2397-2405 (Pubitemid 40490151)
22. Kanakkanthara A, Northcote PT, Miller JH (2012) βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol Cancer Ther 11(2):393-404
23. Cheung CH, Wu SY, Lee TR, Chang CY, Wu JS, Hsieh HP, Chang JY (2010) Cancer cells acquire mitotic drug resistance properties through βI-tubulin mutations and alterations in the expression of β-tubulin isotypes. PLoS ONE 5(9):e12564
24. Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, Nakagawa K (2002) Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 35(1):11-16 (Pubitemid 34028085)
25. Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI (2002) Conservation of the class I β-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 1(3):215-225
26. Mesquita B, Veiga I, Pereira D, Tavares A, Pinto IM, Pinto C, Teixeira MR, Castedo S (2005) No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 5:101 (Pubitemid 41461034)
27. Shimomura M, Yaoi T, Itoh K, Kato D, Terauchi K, Shimada J, Fushiki S (2012) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int J Oncol 40(4):995-1004
28. Thiele A, Krentzlin K, Erdmann F, Rauh D, Hause G, Zerweck J, Kilka S, Posel S, Fischer G, Schutkowski M, Weiwad M (2011) Parvulin 17 promotes microtubule assembly by its peptidyl-prolyl cis/trans isomerase activity. J Mol Biol 411(4):896-909
29. Lee J (2010) Role of cyclophilin a during oncogenesis. Arch Pharm Res 33(2):181-187
30. González-Santiago L, Alfonso P, Suárez Y, Núñez A, García-Fernández LF, Alvarez E, Muñoz A, Casal JI (2007) Proteomic analysis of the resistance to aplidin in human cancer cells. J Proteome Res 6(4):1286-1294 (Pubitemid 46724025)
31. Fojo T, Menefee M (2007) Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18(Suppl 5):v3-v8
32. Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF (2010) Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 37(1):115-120
33. Kanwar JR, Kamalapuram SK, Kanwar RK (2010) Targeting survivin in cancer: patent review. Expert Opin Ther Pat 20(12):1723-1737
34. Zhang XC, Wang WD, Wang JS, Pan JC (2013) PPIase independent chaperone-like function of recombinant human cyclophilin A during arginine kinase refolding. FEBS Lett 587(6):666-672
35. Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, Guo H, Hung HC, Toole B, Gallay P, Sherry B, Bukrinsky M (2002) Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 277(25):22959-22965 (Pubitemid 34967280)
36. Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW (2007) Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 25(1):54-64 (Pubitemid 44765217)
37. Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, Yao Q (2006) Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 106(10):2284-2294 (Pubitemid 43673252)
38. Yang H, Chen J, Yang J, Qiao S, Zhao S, Yu L (2007) Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 361(3):763-767 (Pubitemid 47238044)
39. Obchoei S, Weakley SM, Wongkham S, Wongkham C, Sawanyawisuth K, Yao Q, Chen C (2011) Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer 10:102
40. Qian Z, Zhao X, Jiang M, Jia W, Zhang C, Wang Y, Li B, Yue W (2012) Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9. BMC Cancer 12:442
41. Li Z, Gou J, Xu J (2013) Down-regulation of focal adhesion signaling in response to cyclophilin A knockdown in human endometrial cancer cells, implicated by cDNA microarray analysis. Gynecol Oncol. doi: 10.1016/j.ygyno. 2013.07.095